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Introduction
Colorectal cancer (CRC) is one of the most common 
cancers and is the 2nd leading cause of cancer death in 
men and women in the United States (Stone et al., 2004) 
and also is third common cancer in women and 5th in 
Iranian men (Azadeh et al., 2008).
Although all platinum analogs are potentially 
neurotoxic, oxaliplatin is associated with a unique spectrum 
of neurologic symptoms (Park et al., 2009). The peripheral 
nervous system can be vulnerable to the toxic action of 
several drugs since it is not protected as effectively as the 
central nervous system from noxious exogenous agents. 
Drug-induced neurotoxicity can affect the nerve fibers or 
the neuronal bodies (generally the dorsal root ganglia of 
the primary sensory neurons). Among the neurotoxic drugs 
antineoplastic agents represent a major clinical problem, 
given their widespread use and the potential severity 
of their toxicity (Argyriou et al., 2012). Infusion of the 
chemotherapeutic agent oxaliplatin leads to an acute and 
a chronic form of peripheral neuropathy. Acute oxaliplatin 
neuropathy is characterized by sensory paresthesias 
and muscle cramps that are notably exacerbated by 
cooling. Painful dysesthesias are rarely reported for acute 
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Abstract
 Background: The chemotherapeutic agent oxaliplatin can cause acute and chronic forms of peripheral 
neuropathy. The aim of this study was to evaluate the incidence of chronic neuropathy and its risk factors in 
colorectal cancer (CRC) patients treated with FOLFOX or XELOX regimens in the Oncology Ward of Hazrat-
e-Rasoul Hospital in Tehran. Materials and Methods: A total of 130 patients with CRC were entered into our 
study, aged over 18 years, without history of receiving other neurotoxic agents or other predisposing factors such 
as diabetes or neurologic diseases and kidney and liver dysfunction. For the FOLFOX regimen, patients received 
oxaliplatin, 85 mg/m2, every 2 weeks for 12 courses and with the XELOX regimen, oxaliplatin was 130mg/m2, 
every 3 weeks for 8 courses. Based on Common Toxicity Criteria (CTC or NCI-CTC v.3), the patients were 
divided into 5 groups (grades) based on the severity of their symptoms. Results: Fifty-seven patients (43.8%) 
were male and 73(56.2%) female. Some 19 patients (14.7%) had BMI<20, 97(74.6%) were between 20-25 and 
14 (10.8%) ≥25. In 105 patients (80.7%) neuropathy was found. There was significant correlation between BMI, 
hypomagnesaemia and especially, severity of anemia in patients with neuropathy compared to those without. 
Conclusions: Oxaliplatin regimens can induce chronic neuropathy in CRC patients, with anemia, high BMI and 
hypomagnesaemia as risk factors that can predispose to this kind of neurotoxicity. 
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oxaliplatin neuropathy, whereas a common symptom of 
chronic oxaliplatin neuropathy is pain (Sittl et al., 2012). 
Calcium and magnesium solutions are an effective and 
convenient means of treating and reducing the severity 
of neuropathic symptoms( Cersosimo, 2005). 
Capecitabin is an oral fluoropyrimidine with similar 
efficacy to bolus 5-fluorouracil/folinic acid (5-FU/FA) 
in the first-line treatment of metastatic colorectal cancer 
and as adjuvant therapy for stage III colon cancer and 
also the efficacy of capecitabine and a 3-weekly dose of 
oxaliplatin (XELOX regimen) is also non-inferior to 5-FU/
FA plus oxaliplatin (FOLFOX) in the first- and second-
line treatment of patients with metastatic colorectal cancer 
(Cassidy et al., 2011).
The aim of study is to evaluated incidence of chronic 
neuropathy and its risk factors in CRC patients that treated 
with FOLFOX or XELOX regimen in Tehran province, 
Iran. 
Materials and Methods
Of all referred CRC patients to Oncology Clinic, 
Hazrat-e-Rasoul Hospital, Tehran, Iran, 130 CRC 
patients were entered to our study that were treating with 
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Oxaliplatin, age>18 years, not having of history of other 
chemotherapy and also these patients didn’t have previous 
neuropathy history, polymyositis, kidney and liver failure. 
The patients were treated with adjuvant chemotherapy 
regimen of FOLFOX (5-Flourouracil, leucovorin, 
oxaliplatin) or XELOX (capecitabine plus oxaliplatin). 
In FOLFOX regimen patients received oxaliplatin, 85mg/
m2 every 2 weeks for 12 courses and in XELOX regimen, 
130mg/m2 every 3 weeks for 8 courses. The evaluation 
for neuropathy was done before starting treatment, after 
fourth course of XELOX or sixth course of FOLFOX, 
at the end of treatment; and also 3 months and 6 month 
after last course. Before treatment, complete blood count 
(CBC), serum calcium and serum magnesium levels were 
evaluated in all of the patients. 
Based on Common Toxicity Criteria (CTC or NCI-
CTC v.3), the patients were divided to 5 groups based 
on the grade of neurotoxicity (Table 1)(Vincenzi et 
al., 2013). Also, parameters definition(hypocalcaemia, 
hypomagnesaemia, anemia, diabetes, alcohol consumption) 
has been written in Table 2 (Vincenzi et al., 2013). In this 
study, we evaluated only chronic peripheral neuropathy 
by oxaliplatin.
The correlation between variables was done by IBM 
SPSS statistics v.19 (Chi-square test) that P<0.05 was 
statistically significant.
Results 
Of 130 CRC patients, 67 patients (51.5%) had age>60 
years and 63 patients (48.5%) had ≥60 years. Fifty-seven 
patients (43.8%) were male and 73(56.2%) female. Body 
mass index (BMI) was divided to 3 groups that 19 patients 
(14.65%) <20, 97(74.6%) between 20-25 and 14(10.8%) 
≥25. In our patients, 105 patients(80.7%) had neuropathy, 
28 patients(21.5%) had diabetes, 98 patients(75.3%) had 
anemia, 25 patients(19.3) had hypocalcaemia, 18 patients 
(13.8%) had hypomagnesaemia and 5 patients (3.8%) were 
consuming alcohol (Table 1).
Table 1. The Characteristics of the Patients (n=130)
Variables  n(%)
Age >60 67(51.5)
 ≤60 63(48.5)
Sex Male 57(43.8)
 Female 73(56.2)
BMI* <20 19(14.6)
 20-25 97(74.6)
 ≥25 14(10.8)
Neuropathy  Yes 105(80.7)
 No 25(19.3)
Diabetes Yes 28(21.5)
 No 102(78.5)
Anemia Yes 98(75.3)
 No 32(24.7)
Hypocalcaemia Yes 25(19.3)
 No 105(80.7)
Hypomagnesaemia Yes 18(13.8)
 No 112(86.2)
Alcohol consumption Yes 5(3.8)
 No 125(96.2)
* Body Mass Index
Table 2. The Correlation between Neuropathy and 
Some other Variables in Colorectal Cancer Patients 
(n=130)
Variables, n(%)  Neuropathy  P-value*
 Yes(n=105) No(n=25) 
Age   0.68
      >60 52(49.5) 15(60) 
      ≤60 53(50.5) 10(40) 
Sex    0.83
     Male 52(49.5) 5(20) 
     Female 53(50.5) 20(80) 
BMI*   0.003
      <20 8(7.6) 11(44) 
      20-25 84(80) 13(52) 
      ≥25 13(12.4) 1(4) 
Diabetes   0.54
       Yes 22(21) 6(24) 
       No 83(79) 19(76) 
Anemia   0.004
       Yes 85 (81) 13(52) 
       No 20(19) 12(48) 
 Hypocalcaemia   0.148
       Yes 20(19) 5(20) 
       No 85(81) 20(80) 
Hypomagnesaemia   0.045
       Yes 17(16.2) 1(4) 
       No 88(83.8) 24(96) 
 Alcohol consumption   0.82
       Yes 2(1.9) 3(12) 
       No 103(98.1) 22(88) 
*Chi-square test
Table 3. The Prevalence of Grades of Neuropathy with 
a Number of Variables in Colorectal Cancer Patients
Variables, n(%) Grade 1 Grade 2 Grade 3 P-value*
Age    0.78
      >60 8(47.1) 27(47.4) 17(54.8) 
      ≤60 9(52.9) 31(52.6) 13(45.2) 
Sex     0.882
     Male 8(47.1) 28(48.3) 16(53.3) 
     Female 9(52.9) 30(51.7) 14(46.7) 
Anemia    0
     Yes 8(47.1) 52(89.7) 25(83.3) 
     No 9(52.9) 6(10.3) 5(16.7) 
Hypomagnesaemia    0.42
     Yes 4(23.5) 7(12.1) 6(20) 
     No 13(76.5) 51(87.9) 24(80) 
Hypocalcaemia    0.267
      Yes 4(30) 8(13.8) 8(23.5) 
      No 9(69.2) 50(86.2) 26(76.5) 
Diabetes    0.072
      Yes 7(41.2) 9(15.5) 6(20) 
      No  10(58.8) 49(84.5) 24(80) 
*Chi-square test
Table 4. The Correlation between Neuropathy with 
Chemotherapy Regimens
Chemotherapy regimen, n(%) Total
FOLFOX 87 (66.9)
XELOX 43 (33.1)
Total 130  (100)
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The correlation between neuropathy with a number of 
variables in CRC has been shown in Table 2. In the patients 
with neuropathy, more had high BMI that this correlation 
was statistically significant (P=0.003). In addition, anemia 
and hypomagnesaemia in the patients with neuropathy 
were more than the patients without neuropathy (P<0.05).
 Table 3 shows the distribution of grades of neuropathy 
in relation with other of variables in CRC patients. In 
our study, there were no grade 0 and grade 4. There was 
the close correlation between anemia and severity of 
neuropathy (P= 0.000). 
Of 133 CRC patients, 87(66.9%) patients were treated 
with FOLFOX regimen and 43(33.1%) patients with 
XELOX regimen (Table 4). There was no correlation 
between regimens with neuropathy (P=0.14).
Discussion
CRC is the third most common neoplastic disease 
worldwide. It is one of the leading causes of cancer 
mortality, accounting for about 10% of all cancer deaths, 
with approximately 40%-50% of all cases diagnosed as 
metastatic (Payandeh et al., 2015). Peripheral neuropathy 
ranks among the most common non-haematological 
adverse effects of a number of effective chemotherapeutic 
agents, including platinum compounds, taxanes and vinca 
alkaloids. Chemotherapy-induced peripheral neuropathy 
(CIPN) may result from a variety of mechanisms and 
may be related to causal factors, such as single dose 
per course, cumulative dose and risk factors including 
treatment schedule, prior or concomitant administration 
of other neurotoxic agents, age and pre-existing peripheral 
neuropathy of other causes (Argyriou et al., 2010). The 
advent of monoclonal antibodies such as cetuximab and 
bevacizumab has further broadened the treatment horizon 
for colorectal cancer and they are the focus of the on-going 
randomized studies in adjuvant therapy of colon cancer 
(Chau I and Cunningham D.,2006). Adding oxaliplatin 
to a regimen of fluorouracil and leucovorin improves the 
adjuvant treatment of colon cancer (André et al., 2004).
In a study, (Rothenberg et al., 2008) 627 patients were 
randomly assigned to receive XELOX (n = 313) or FOLFOX 
(n=314) following disease progression/recurrence or 
intolerance to irinotecan-based chemotherapy. XELOX 
was non-inferior to FOLFOX when administered as 
second-line treatment in patients with metastatic colorectal 
cancer.In other study, (Argyriou et al., 2007) twenty-five 
adult patients scheduled to be treated with 12 courses of 
the oxaliplatin-based regimen, FOLFOX-4, for metastatic 
colon cancer. The results indicate that the majority of 
patients treated with the FOLFOX-4 regimen would 
manifest an axonal, predominately sensory peripheral 
neuropathy, of mild to moderate severity. 
420 untreated CRC patients were randomized to 
receive a 2-hour infusion of leucovorin (200 mg/m2/d) 
followed by a 5-fluorouracil bolus (400 mg/m2/d) and 
22-hour infusion (600 mg/m2/d) for 2 consecutive days 
every 2 weeks, either alone or together with oxaliplatin 
85 mg/m2 as a 2-hour infusion on day 1. The grade 3 
neurosensory toxicity was 18.2% versus 0%. Therefore, 
leucovorin, 5-fluorouracil and oxaliplatin combination 
seems beneficial as first-line therapy in advanced 
colorectal cancer (Gramont et al., 2000).
A research showed that oxaliplatin/leucovorin/5-
fluorouracil regimen demonstrated substantial efficacies 
and manageable toxicity profiles in the first-line treatment 
of patients with advanced CRC. (7) Other report showed 
that there was oxaliplatin-induced peripheral neuropathy 
in patients with CRC treated with either FOLFOX or 
XELOX and the incidence of acute neurotoxicity during 
FOLFOX therapy was similar to XELOX, but FOLFOX 
was associated with increased incidence of chronic 
neurotoxicity, compared with XELOX-treated patients 
(Meyerhardt et al., 2004). Incidence of acute peripheral 
neuropathy during XELOX appears similar to FOLFOX, 
but chronic peripheral neuropathy in adjuvant patients 
may be more common with XELOX (Storey et al., 2010).
100 patients treated with adjuvant FOLFOX and 266 
patients treated with XELOX. The median cumulative 
dose of oxaliplatin was 796 mg/m2(range, 85 to 1,583 mg/
m2). Overall, 43 patients discontinued chemotherapy due 
to toxicity (Baek et al., 2010). Patients with metastatic 
CRC received first-line XELOX in 3-week treatment 
cycles: intravenous oxaliplatin 130 mg/m(2) (day 1) 
followed by oral capecitabine 1,000 mg/m(2) twice daily 
(day 1, evening, up to day 15, morning). XELOX safety 
was predictable and similar to the FOLFOX4 regimen, 
except that myelosuppression was uncommon with 
XELOX (grade 3 or 4 neutropenia, 7%). Most adverse 
events were mild to moderate, the most common being 
acute sensory neuropathy (85%) (Cassidy et al., 2004). 
Also, in a study reported that that 5-fluorouracil or 
its active metabolites were contributing factors to the 
peripheral neuropathy (Saif et al., 2001). In our study, 
of 133 CRC patients treated with FOLFOX or XELOX, 
overall 105 patients (80.7%) had chronic neuropathy 
and also there was correlation between these regimens 
with incidence of neuropathy(P>0.05). Based on these 
results, it is clear that oxaliplatin in both regimens can 
induce neuropathy with high incidence especially chronic 
neuropathy in CRC patients, but dose and number of 
courses for oxaliplatin in chemotherapy regimens can 
change percentage of neuropathy in patients. In future 
studies can check this subject that a study reported chronic 
neuropathy is cumulative and is most commonly seen in 
patients who have received total doses > or =540 mg/m2 
(Cersosimo, 2005).
Anemia, albumin level, chronic renal failure, number 
of cycles, alcohol consumption and hypomagnesaemia 
were variables that in CRC patients had significant 
correlation with grade of neuropathy (high incidence for 
these variables equals with high grade) (Vincenzi et al., 
2013). In CRC patients, greater BMI potentially associate 
with persistent neuropathy, but in contrast to weight, 
height was not an informative factor; as a result, BMI 
(weight adjusted for height) did not predict neuropathy as 
efficiently as weight alone did (Alejandro et al., 2013). A 
number studies on the mechanism of peripheral sensory 
neurotoxicity (PSN) reported that calcium and magnesium 
replacement effectively reduced chronic PSN, suggesting 
that these supplements are efficacious (Gamelin et al., 
2002; Gamelin et al., 2004; Kono et al., 2010). In our 
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study, anemia just had significant correlation with grade of 
neuropathy. In CRC patients with anemia, there is high risk 
for incidence of neuropathy with high grade. In addition, 
BMI and hypomagnesaemia had significant correlation 
with incidence of neuropathy, but there is correlation these 
variables with grade.
In conclusion, Oxaliplatin regimens can induce chronic 
neuropathy in CRC patients, but these are almost similar 
in incidence of neuropathy. Anemia, high BMI and 
hypomagnesaemia are risk factors that can predispose to 
this kind of neurotoxicity. Oncologists should pay special 
attention to high incidence of neuropathy in CRC patients 
that have anemia and receive oxaliplatin regimens.
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